Sucampo Pharmaceuticals, Inc. Class A
(NASDAQ : SCMP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Loading SCMP News...
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
-0.29%125.530.6%$974.28m
PFEPfizer Inc.
-0.82%34.011.9%$797.03m
MRKMerck & Co., Inc.
-0.14%63.190.6%$590.05m
BMYBristol-Myers Squibb Company
0.25%55.912.8%$587.15m
ABBVAbbVie, Inc.
-0.03%65.631.9%$429.97m
LLYEli Lilly and Company
-0.26%84.201.1%$313.42m
NVSNovartis AG Sponsored ADR
-0.08%74.370.2%$215.25m
AZNAstraZeneca PLC Sponsored ADR
0.00%31.301.1%$155.11m
GSKGlaxoSmithKline plc Sponsored ADR
0.01%42.320.3%$111.26m
NVONovo Nordisk A/S Sponsored ADR Class B
1.21%33.550.1%$70.19m
SNYSanofi Sponsored ADR
0.25%44.620.2%$62.32m
LCILannett Company, Inc.
1.18%21.4536.7%$15.34m
SCMPSucampo Pharmaceuticals, Inc. Class A
-1.40%10.6015.6%$10.22m
AKTXAkari Therapeutics Plc Sponsored ADR
0.85%6.500.1%$0.13m
EPIXESSA Pharma Inc
-6.01%2.950.0%$0.03m

Company Profile

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs in the Americas, Europe and Asia. It is developing prostones, which are ion channel activators, to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders, as well as other therapeutic applications of drug technologies. The company's product pipeline includes AMITIZA for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product pipeline also consists of Unoprostone Isopropyl, which is in Phase III trial for the treatment of retinitis pigmentosa and in pre-clinical stage for the treatment of geographic atrophy; and Cobiprostone that has completed Phase Ib trial for the treatment of oral mucositis, as well as in Phase II trial for the treatment of non-erosive reflux diseases. Sucampo Pharmaceuticals was founded by Dr. Ryuji Ueno and Dr. Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.